findmyKOL
Clinical trialNCT03834766CompletedPhase 3Interventional

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

SponsorTris Pharma, Inc.Enrollment130ADHD
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Meridien Research

    Bradenton, Florida, United States

  • Meridien Research, Inc.

    Maitland, Florida, United States

  • Center for Psychiatry and Behavioral Medicine

    Las Vegas, Nevada, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AMPH ER Tab 5, 10, 15 and 20 mgAMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Feb 2019
Primary completion
19 Oct 2019
Completion
19 Oct 2019
Last update posted
2 Nov 2023
Registered enrollment
130
Registry id
NCT03834766
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.